Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 26
Filtrar
Más filtros













Base de datos
Intervalo de año de publicación
1.
J Pharmacol Exp Ther ; 366(3): 527-540, 2018 09.
Artículo en Inglés | MEDLINE | ID: mdl-29945932

RESUMEN

Atypical dopamine transporter (DAT) inhibitors, despite high DAT affinity, do not produce the psychomotor stimulant and abuse profile of standard DAT inhibitors such as cocaine. Proposed contributing features for those differences include off-target actions, slow onsets of action, and ligand bias regarding DAT conformation. Several 3α-(4',4''-difluoro-diphenylmethoxy)tropanes were examined, including those with the following substitutions: N-(indole-3''-ethyl)- (GA1-69), N-(R)-2''-amino-3''-methyl-n-butyl- (GA2-50), N-2''aminoethyl- (GA2-99), and N-(cyclopropylmethyl)- (JHW013). These compounds were previously reported to have rapid onset of behavioral effects and were presently evaluated pharmacologically alone or in combination with cocaine. DAT conformational mode was assessed by substituted-cysteine accessibility and molecular dynamics (MD) simulations. As determined by substituted-cysteine alkylation, all BZT analogs except GA2-99 showed bias for a cytoplasmic-facing DAT conformation, whereas cocaine stabilized the extracellular-facing conformation. MD simulations suggested that several analog-DAT complexes formed stable R85-D476 "outer gate" bonds that close the DAT to extracellular space. GA2-99 diverged from this pattern, yet had effects similar to those of other atypical DAT inhibitors. Apparent DAT association rates of the BZT analogs in vivo were slower than that for cocaine. None of the compounds was self-administered or stimulated locomotion, and each blocked those effects of cocaine. The present findings provide more detail on ligand-induced DAT conformations and indicate that aspects of DAT conformation other than "open" versus "closed" may facilitate predictions of the actions of DAT inhibitors and may promote rational design of potential treatments for psychomotor-stimulant abuse.


Asunto(s)
Conducta Animal/efectos de los fármacos , Benzotropina/química , Benzotropina/farmacología , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática/metabolismo , Nitrógeno/química , Animales , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática/química , Masculino , Simulación de Dinámica Molecular , Conformación Proteica , Ratas , Ratas Sprague-Dawley
2.
ACS Chem Biol ; 13(8): 2288-2299, 2018 08 17.
Artículo en Inglés | MEDLINE | ID: mdl-29893552

RESUMEN

Genetic and epigenetic alterations in FK506-binding protein 5 ( FKBP5) have been associated with increased risk for psychiatric disorders, including post-traumatic stress disorder (PTSD). Some of these common variants can increase the expression of FKBP5, the gene that encodes FKBP51. Excess FKBP51 promotes hypothalamic-pituitary-adrenal (HPA) axis dysregulation through altered glucocorticoid receptor (GR) signaling. Thus, we hypothesized that GR activity could be restored by perturbing FKBP51. Here, we screened 1280 pharmacologically active compounds and identified three compounds that rescued FKBP51-mediated suppression of GR activity without directly activating GR. One of the three compounds, benztropine mesylate, disrupted the association of FKBP51 with the GR/Hsp90 complex in vitro. Moreover, we show that removal of FKBP51 from this complex by benztropine restored GR localization in ex vivo brain slices and primary neurons from mice. In conclusion, we have identified a novel disruptor of the FKBP51/GR/Hsp90 complex. Targeting this complex may be a viable approach to developing treatments for disorders related to aberrant FKBP51 expression.


Asunto(s)
Benzotropina/farmacología , Depresión/tratamiento farmacológico , Proteínas HSP90 de Choque Térmico/metabolismo , Receptores de Glucocorticoides/metabolismo , Trastornos por Estrés Postraumático/tratamiento farmacológico , Proteínas de Unión a Tacrolimus/metabolismo , Animales , Benzotropina/química , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Células Cultivadas , Depresión/metabolismo , Descubrimiento de Drogas , Humanos , Ratones , Terapia Molecular Dirigida , Unión Proteica/efectos de los fármacos , Trastornos por Estrés Postraumático/metabolismo , Proteínas de Unión a Tacrolimus/antagonistas & inhibidores
3.
J Med Chem ; 60(24): 10172-10187, 2017 12 28.
Artículo en Inglés | MEDLINE | ID: mdl-29227643

RESUMEN

The development of medications to treat cocaine use disorders has thus far defied success, leaving this patient population without pharmacotherapeutic options. As the dopamine transporter (DAT) plays a prominent role in the reinforcing effects of cocaine that can lead to addiction, atypical DAT inhibitors have been developed that prevent cocaine from binding to DAT, but they themselves are not cocaine-like. Herein, a series of novel DAT inhibitors were synthesized, and based on its pharmacological profile, the lead compound 10a was evaluated in phase I metabolic stability studies in mouse liver microsomes and compared to cocaine in locomotor activity and drug discrimination paradigms in mice. A molecular dynamic simulation study supported the hypothesis that atypical DAT inhibitors have similar binding poses at DAT in a conformation that differs from that of cocaine. Such differences may ultimately contribute to their unique behavioral profiles and potential for development as cocaine use disorder therapeutics.


Asunto(s)
Proteínas de Transporte de Dopamina a través de la Membrana Plasmática/antagonistas & inhibidores , Evaluación Preclínica de Medicamentos/métodos , Relación Estructura-Actividad , Animales , Benzotropina/química , Células COS , Chlorocebus aethiops , Trastornos Relacionados con Cocaína/tratamiento farmacológico , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática/genética , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática/metabolismo , Humanos , Locomoción/efectos de los fármacos , Masculino , Ratones , Microsomas Hepáticos/efectos de los fármacos , Simulación de Dinámica Molecular , Proteínas de Transporte de Noradrenalina a través de la Membrana Plasmática/metabolismo , Proteínas de Unión al ARN/metabolismo , Ratas Sprague-Dawley , Tropanos/química
4.
J Chromatogr Sci ; 55(9): 961-968, 2017 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-29048492

RESUMEN

Two accurate, precise and highly selective stability-indicating methods were adopted for simultaneous determination of benztropine mesylate (BNZ) in presence of its hepatotoxic and carcinogenic degradation product, benzophenone (BPH) either in pure form or in the pharmaceutical formulation without any preliminary separation steps. The first method is a thin layer chromatography (TLC)-densitometric method that depended on separation of BNZ from its degradate on TLC aluminum plates precoated with silica gel 60 F254 as the stationary phase using a developing system consisted of hexane:methylene chloride:triethylamine (5:5:0.6, by volume) and scanning the separated bands at 235 nm. Linear regression analysis data for the calibration plots of BNZ and BPH showed perfect linear relationships over the concentration range of 1.5-10 and 1-10 µg band-1, respectively. The second method is (UPLC) method, at which the mixture was separated on a reversed phase C8 analytical column (1.9 µm ps, 50 mm × 2.1 i.d.) using a mobile phase of acetonitrile: aqueous sodium dodecyl sulfate (50:50, v/v) Adjusted to pH = 3 with phosphoric acid, at a flow rate of 0.5 mL min-1. Quantification was achieved at 210 nm based on peak area and linear calibration curves over the concentration ranges of (20-200 µg mL-1) and (5-50 µg mL-1) for BNZ and BPH, respectively, were obtained. The investigated methods were successfully applied to available dosage form and method validation has been carried out. The results obtained by applying the proposed methods were statistically analyzed and compared with those obtained by reported one and no significant differences were obtained regarding both accuracy and precision.


Asunto(s)
Benzotropina/análisis , Benzotropina/química , Cromatografía Líquida de Alta Presión/métodos , Cromatografía en Capa Delgada/métodos , Carcinógenos/análisis , Carcinógenos/química , Densitometría/métodos , Estabilidad de Medicamentos , Límite de Detección , Modelos Lineales , Reproducibilidad de los Resultados
5.
J Mol Graph Model ; 76: 143-151, 2017 09.
Artículo en Inglés | MEDLINE | ID: mdl-28734204

RESUMEN

The recreational psychostimulant cocaine inhibits dopamine reuptake from the synapse, resulting in excessive stimulation of postsynaptic dopamine receptors in brain areas associated with reward and addiction. Cocaine binds to and stabilizes the outward- (extracellular-) facing conformation of the dopamine transporter (DAT) protein, while the low abuse potential DAT inhibitor benztropine prefers the inward- (cytoplasmic-) facing conformation. A correlation has been previously postulated between psychostimulant abuse potential and preference for the outward-facing DAT conformation. The 3ß-aryltropane cocaine analogs LX10 and LX11, however, differ only in stereochemistry and share a preference for the outward-facing DAT, yet are reported to vary widely in abuse potential in an animal model. In search of the molecular basis for DAT conformation preference, complexes of cocaine, benztropine, LX10 or LX11 bound to each DAT conformation were subjected to 100ns of all-atom molecular dynamics simulation. Results were consistent with previous findings from cysteine accessibility assays used to assess an inhibitor's DAT conformation preference. The respective 2ß- and 2α-substituted phenyltropanes of LX10 and LX11 interacted with hydrophobic regions of the DAT S1 binding site that were inaccessible to cocaine. Solvent accessibility measurements also revealed subtle differences in inhibitor positioning within a given DAT conformation. This work serves to advance our understanding of the conformational selectivity of DAT inhibitors and suggests that MD may be useful in antipsychostimulant therapeutic design.


Asunto(s)
Proteínas de Transporte de Dopamina a través de la Membrana Plasmática/química , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática/metabolismo , Dopamina/química , Dopamina/metabolismo , Animales , Benzotropina/química , Benzotropina/metabolismo , Sitios de Unión/fisiología , Cocaína/química , Cocaína/metabolismo , Simulación de Dinámica Molecular , Unión Proteica/fisiología , Conformación Proteica
6.
Br J Pharmacol ; 174(6): 468-482, 2017 03.
Artículo en Inglés | MEDLINE | ID: mdl-28176326

RESUMEN

BACKGROUND AND PURPOSE: The neutral amino acid transporter B0 AT1 (SLC6A19) has recently been identified as a possible target to treat type 2 diabetes and related disorders. B0 AT1 mediates the Na+ -dependent uptake of all neutral amino acids. For surface expression and catalytic activity, B0 AT1 requires coexpression of collectrin (TMEM27). In this study, we established tools to identify and evaluate novel inhibitors of B0 AT1. EXPERIMENTAL APPROACH: A CHO-based cell line was generated, stably expressing collectrin and B0 AT1. Using this cell line, a high-throughput screening assay was developed, which uses a fluorescent dye to detect depolarisation of the cell membrane during amino acid uptake via B0 AT1. In parallel to these functional assays, we ran a computational compound screen using AutoDock4 and a homology model of B0 AT1 based on the high-resolution structure of the highly homologous Drosophila dopamine transporter. KEY RESULTS: We characterized a series of novel inhibitors of the B0 AT1 transporter. Benztropine was identified as a competitive inhibitor of the transporter showing an IC50 of 44 ± 9 µM. The compound was selective with regard to related transporters and blocked neutral amino acid uptake in inverted sections of mouse intestine. CONCLUSION AND IMPLICATIONS: The tools established in this study can be widely used to identify new transport inhibitors. Using these tools, we were able to identify compounds that can be used to study epithelial transport, to induce protein restriction, or be developed further through medicinal chemistry.


Asunto(s)
Sistemas de Transporte de Aminoácidos Neutros/antagonistas & inhibidores , Benzotropina/farmacología , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Sistemas de Transporte de Aminoácidos/química , Sistemas de Transporte de Aminoácidos/metabolismo , Sistemas de Transporte de Aminoácidos Neutros/metabolismo , Animales , Benzotropina/química , Células CHO , Cricetulus , Diabetes Mellitus Tipo 2/metabolismo , Relación Dosis-Respuesta a Droga , Drosophila , Femenino , Ensayos Analíticos de Alto Rendimiento , Masculino , Ratones , Ratones Endogámicos C57BL , Simulación del Acoplamiento Molecular , Relación Estructura-Actividad
7.
Psychopharmacology (Berl) ; 229(2): 307-21, 2013 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-23612854

RESUMEN

RATIONALE: Dopamine transporter (DAT) conformation plays a role in the effectiveness of cocaine-like and other DAT inhibitors. Cocaine-like stimulants are intolerant to DAT conformation changes having decreased potency in cells transfected with DAT constructs that face the cytosol compared to wild-type DAT. In contrast, analogs of benztropine (BZT) are among compounds that are less affected by DAT conformational change. METHODS: We compared the displacement of radioligand binding to various mammalian CNS sites, acute stimulation of accumbens shell dopamine levels, and place conditioning in rats among cocaine and four BZT analogs with Cl substitutions on the diphenyl-ether system including two with carboalkoxy substitutions at the 2-position of the tropane ring. RESULTS: Binding assays confirmed high-affinity and selectivity for the DAT with the BZT analogs which also produced significant stimulation of mesolimbic dopamine efflux. Because BZT analogs produced temporal patterns of extracellular dopamine levels different from those by cocaine (3-10 mg/kg, i.p.), the place conditioning produced by BZT analogs and cocaine was compared at doses and times at which both the increase in dopamine levels and rates of increase were similar to those produced by an effective dose of cocaine. Despite this equilibration, none of the BZT analogs tested produced significant place conditioning. CONCLUSIONS: The present results extend previous findings suggesting that cocaine-like actions are dependent on a binding equilibrium that favors the outward conformational state of the DAT. In contrast, BZT analogs with reduced dependence on DAT conformation have reduced cocaine-like behavioral effects and may prove useful in development of medications for stimulant abuse.


Asunto(s)
Cocaína/farmacología , Condicionamiento Operante/efectos de los fármacos , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática/metabolismo , Inhibidores de Captación de Dopamina/farmacología , Dopamina/metabolismo , Núcleo Accumbens/efectos de los fármacos , Análisis de Varianza , Animales , Benzotropina/análogos & derivados , Benzotropina/química , Benzotropina/farmacología , Sitios de Unión/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Masculino , Microdiálisis , Núcleo Accumbens/metabolismo , Conformación Proteica/efectos de los fármacos , Ensayo de Unión Radioligante , Ratas , Ratas Sprague-Dawley , Factores de Tiempo
8.
Bioorg Med Chem Lett ; 22(3): 1448-54, 2012 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-22243960

RESUMEN

Using structure-based optimization procedures on in silico hits, dibenzosuberyl- and benzoate substituted tropines were designed as ligands for acetylcholine-binding protein (AChBP). This protein is a homolog to the ligand binding domain of the nicotinic acetylcholine receptor (nAChR). Distinct SAR is observed between two AChBP species variants and between the α7 and α4ß2 nAChR subtype. The AChBP species differences are indicative of a difference in accessibility of a ligand-inducible subpocket. Hereby, we have identified a region that can be scrutinized to achieve selectivity for nicotinic receptor subtypes.


Asunto(s)
Caprilatos/química , Ácidos Dicarboxílicos/química , Diseño de Fármacos , Ligandos , Receptores Nicotínicos/química , Benzotropina/química , Proteínas Portadoras/metabolismo , Modelos Moleculares , Unión Proteica , Relación Estructura-Actividad
9.
Neurosci Lett ; 451(3): 212-6, 2009 Feb 27.
Artículo en Inglés | MEDLINE | ID: mdl-19159658

RESUMEN

The mammalian proline transporter (PROT) is a high affinity Na(+)/Cl(-)-dependent transporter expressed in specific regions of the brain. It is homologous to other neurotransmitter transporters such as glycine, norepinephrine, serotonin, and dopamine transporters. PROT is enriched in glutamatergic synaptic terminals and may play an important role in the regulation of excitatory neurotransmission. No non-peptide small molecule inhibitors have been described for this transporter. To study its physiological role in the central nervous system and evaluate its potential as a therapeutic target, we established cell lines that stably express recombinant hPROT and characterized its kinetic properties for proline uptake. We then screened for inhibitors and identified a series of compounds that inhibit hPROT-mediated proline uptake. A known compound, benztropine, was found to inhibit hPROT with an IC(50) of 0.75microM. A series of novel compounds were also found, one of which, LP-403812, showed an IC(50) of approximately 0.1microM on both recombinant human and mouse PROT without significant inhibition of glycine and dopamine transporters at concentrations up to 10microM. This compound also inhibited proline transporter activity of mouse brain synaptosomes with the same potency. These inhibitors provide important tools for the understanding of PROT functions in the brain and may lead to the development of therapeutic agents for certain neurological disorders.


Asunto(s)
Sistemas de Transporte de Aminoácidos Neutros/antagonistas & inhibidores , Encéfalo/metabolismo , Inhibidores Enzimáticos/farmacología , Terminales Presinápticos/metabolismo , Pirazoles/farmacología , Transmisión Sináptica/efectos de los fármacos , Tiazoles/farmacología , Sistemas de Transporte de Aminoácidos Neutros/genética , Sistemas de Transporte de Aminoácidos Neutros/metabolismo , Animales , Secuencia de Bases , Benzotropina/química , Benzotropina/farmacología , Encéfalo/ultraestructura , Células COS , Línea Celular , Chlorocebus aethiops , Clonación Molecular , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos/métodos , Inhibidores Enzimáticos/aislamiento & purificación , Humanos , Ratones , Estructura Molecular , Antagonistas Muscarínicos/farmacología , Terminales Presinápticos/ultraestructura , Proteínas Recombinantes/antagonistas & inhibidores , Proteínas Recombinantes/metabolismo , Transmisión Sináptica/fisiología , Sinaptosomas , Transfección
10.
J Neurochem ; 107(4): 928-40, 2008 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-18786172

RESUMEN

The widely abused psychostimulant cocaine is thought to elicit its reinforcing effects primarily via inhibition of the neuronal dopamine transporter (DAT). However, not all DAT inhibitors share cocaine's behavioral profile, despite similar or greater affinity for the DAT. This may be due to differential molecular interactions with the DAT. Our previous work using transporter mutants with altered conformational equilibrium (W84L and D313N) indicated that benztropine and GBR12909 interact with the DAT in a different manner than cocaine. Here, we expand upon these previous findings, studying a number of structurally different DAT inhibitors for their ability to inhibit [(3)H]CFT binding to wild-type, W84L and D313N transporters. We systematically tested structural intermediates between cocaine and benztropine, structural hybrids of benztropine and GBR12909 and a number of other structurally heterologous inhibitors. Derivatives of the stimulant desoxypipradrol (2-benzhydrylpiperidine) exhibited a cocaine-like binding profile with respect to mutation, whereas compounds possessing the diphenylmethoxy moiety of benztropine and GBR12909 were dissimilar to cocaine-like compounds. In tests with specific isomers of cocaine and tropane analogues, compounds with 3alpha stereochemistry tended to exhibit benztropine-like binding, whereas those with 3beta stereochemistry were more cocaine-like. Our results point to the importance of specific molecular features--most notably the presence of a diphenylmethoxy moiety--in determining a compound's binding profile. This study furthers the concept of using DAT mutants to differentiate cocaine-like inhibitors from atypical inhibitors in vitro. Further studies of the molecular features that define inhibitor-transporter interaction could lead to the development of DAT inhibitors with differential clinical utility.


Asunto(s)
Unión Competitiva/efectos de los fármacos , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática/genética , Inhibidores de Captación de Dopamina/química , Inhibidores de Captación de Dopamina/farmacología , Mutación/genética , Animales , Asparagina/genética , Ácido Aspártico/genética , Benzotropina/química , Benzotropina/farmacología , Línea Celular Transformada , Cocaína/análogos & derivados , Cocaína/química , Cocaína/metabolismo , Cocaína/farmacología , Inhibidores de Captación de Dopamina/metabolismo , Interacciones Farmacológicas , Humanos , Leucina/genética , Modelos Moleculares , Piperazinas/química , Piperazinas/farmacología , Unión Proteica/efectos de los fármacos , Estructura Terciaria de Proteína , Sodio/metabolismo , Relación Estructura-Actividad , Transfección/métodos , Tritio/metabolismo , Triptófano/genética
11.
Int J Pharm ; 357(1-2): 55-60, 2008 Jun 05.
Artículo en Inglés | MEDLINE | ID: mdl-18417307

RESUMEN

Benztropine (BZ) is a potent muscarinic receptor antagonist that has been used for the treatment of Parkinson disease. However, the oral administration of BZ is often limited because of its many dose-related side effects. In this study, BZ was formulated into drug-in adhesive (DIA) patches in an attempt to overcome these problems. The effects of the formulation factors including pressure-sensitive adhesive (PSA), enhancer, the loading amount of the drug and patch thickness on the skin permeation of the drug were evaluated using excised rat skin. The optimized patch contained 10% BZ in Duro-Tak 2525 as a PSA at a thickness of 100 microm. The pharmacokinetic characteristics of the optimized DIA patch were determined after the transdermal application to rabbits. The calculated relative bioavailability of BZ in the DIA patch was 54% compared to the oral administration of BZ mesylate. This suggests that the transdermal application of BZ in a DIA patch may be used for the treatment of Parkinson disease.


Asunto(s)
Benzotropina/administración & dosificación , Benzotropina/farmacocinética , Antagonistas Muscarínicos/administración & dosificación , Antagonistas Muscarínicos/farmacocinética , Administración Cutánea , Animales , Benzotropina/química , Biofarmacia , Fenómenos Químicos , Química Farmacéutica , Química Física , Cromatografía Líquida de Alta Presión , Excipientes , Técnicas In Vitro , Indicadores y Reactivos , Antagonistas Muscarínicos/química , Conejos , Ratas
12.
Bioorg Med Chem ; 14(11): 3625-34, 2006 Jun 01.
Artículo en Inglés | MEDLINE | ID: mdl-16460947

RESUMEN

Benztropine (BZT) and its analogues inhibit dopamine uptake and bind with moderate to high affinity to the dopamine transporter (DAT). However, many of these compounds, in contrast to other monoamine uptake inhibitors, lack cocaine-like behavioral effects and fail to potentiate the effects of cocaine. The BZT analogues also exhibit varied binding affinities for muscarinic M(1) and histamine H(1) receptors. In this study, a comparative analysis was conducted of pharmacophoric features with respect to the activities of BZT analogues at the DAT and at the histamine H(1) receptor. The BZT analogues showed a wide range of histamine H(1) receptor (K(i)=16-37,600 nM) and DAT (K(i)=8.5-6370 nM) binding affinities. A stereoselective histamine H(1)-antagonist pharmacophore, using a five-point superimposition of classical antagonists on the template, cyproheptadine, was developed. A series of superimpositions and comparisons were performed with various analogues of BZT. In general, smaller substituents were well tolerated on the aromatic rings of the diphenyl methoxy group for both the DAT and H(1) receptor, however, for the H(1) receptor, substitution at only one of the aromatic rings was preferred. The substituents at the 2- and N-positions of the tropane ring were preferred for DAT, however, these groups seem to overlap receptor essential regions in the histamine H(1) receptor. Molecular models at the DAT and the histamine H(1) receptor provide further insight into the structural requirements for binding affinity and selectivity that can be implemented in future drug design.


Asunto(s)
Benzotropina/análogos & derivados , Benzotropina/farmacología , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática/antagonistas & inhibidores , Receptores Histamínicos H1/efectos de los fármacos , Animales , Benzotropina/química , Sitios de Unión , Ligandos , Modelos Moleculares , Conformación Molecular , Ratas , Estereoisomerismo , Relación Estructura-Actividad
13.
Bioorg Med Chem Lett ; 15(24): 5419-23, 2005 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-16213721

RESUMEN

A series of N-8-substituted benztropinamines was synthesized and evaluated for binding at the dopamine (DAT), serotonin (SERT), norepinephrine (NET) transporters, and muscarinic M1 receptors. In general, the isosteric replacement of the C-3 benzhydrol ether of benztropine by a benzhydryl amino group was well tolerated at the DAT. However, for certain N-8 substituted derivatives, selectivity over muscarinic M1 receptor affinity was reduced.


Asunto(s)
Benzotropina/química , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática/química , Aminas , Sitios de Unión , Citalopram/química , Cocaína/química , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática/metabolismo , Fluoxetina/análogos & derivados , Fluoxetina/química , Cinética , Ligandos , Modelos Moleculares , Conformación Molecular , Antagonistas Muscarínicos/química , Parasimpatolíticos/química , Pirenzepina/química
14.
Biochem Pharmacol ; 70(3): 461-9, 2005 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-15950948

RESUMEN

A substantial body of evidence suggests that the dopamine transporter (DAT) is the principal site for cocaine-induced reward and euphoria. Interactions between the DAT and its substrates and ligands may therefore be of clinical relevance. The pharmacological characteristics of DAT compounds were compared in wild type (WT) and mutant DATs. The DAT mutants chosen for study were those with reduced binding and uptake activities (aspartic acid 79 mutated to alanine, termed D79A), reduced binding but normal uptake (tyrosine 251 mutated to alanine, termed Y251A; tyrosine 273 mutated to alanine, termed, Y273A), and normal binding but reduced uptake (a double mutation: serines 356 and 359 mutated to alanine, termed S356,359A). The WT and mutant DATs were transfected into COS-7 cells, and their pharmacological activities were examined 3 days later. Different patterns of pharmacological activity emerged. GBR 12909, cocaine, and mazindol each showed reduced affinity for the Y251A and the Y273A mutants, but their affinity for the S356,359A mutant was similar to that of the WT DAT. d-Amphetamine, MPP+, and dopamine each showed reduced affinity for the S356,359A mutant. Benztropine and methylphenidate had a different effect. Relative to the WT DAT, they both showed reduced affinity for the S356,359A mutant when displacing radioactive carboxyfluorotropane (CFT) binding, but similar affinity when inhibiting radioactive dopamine uptake. These results indicate that methylphenidate and benztropine may interact with the DAT in a different fashion then other substrates and ligands.


Asunto(s)
Benzotropina/metabolismo , Glicoproteínas de Membrana/metabolismo , Proteínas de Transporte de Membrana/metabolismo , Metilfenidato/metabolismo , Proteínas del Tejido Nervioso/metabolismo , Secuencia de Aminoácidos , Animales , Benzotropina/química , Benzotropina/farmacología , Sitios de Unión/efectos de los fármacos , Sitios de Unión/fisiología , Células COS , Chlorocebus aethiops , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática , Relación Dosis-Respuesta a Droga , Peces , Ligandos , Masculino , Glicoproteínas de Membrana/química , Glicoproteínas de Membrana/genética , Proteínas de Transporte de Membrana/química , Proteínas de Transporte de Membrana/genética , Metilfenidato/química , Metilfenidato/farmacología , Datos de Secuencia Molecular , Proteínas del Tejido Nervioso/química , Proteínas del Tejido Nervioso/genética , Ratas , Especificidad por Sustrato/efectos de los fármacos , Especificidad por Sustrato/fisiología
15.
Org Biomol Chem ; 2(19): 2861-9, 2004 Oct 07.
Artículo en Inglés | MEDLINE | ID: mdl-15455161

RESUMEN

A combinatorial synthesis of benztropine analogues is presented. Radical azidonation of 3-benzyloxy-8-azabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester 3 to 3-(1-azidobenzyloxy)-8-azabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester 4 was used as a key step in the synthesis. This step was optimized by adding 10% DMF to the reaction. Reaction of 4 with phenyl magnesium bromide followed by Boc removal and N-methylation gave benztropine 1. Reaction of five-component Grignard reagents with 4 was used to create a two-dimensional library of 25 N-normethylbenztropine analogues. Further reaction of this library with five alkyl bromides was carried out to create a three-dimensional library containing 125 compounds. Screening of the libraries towards binding and inhibition of uptake of the human dopamine (hDAT), serotonin (hSERT) and norepinephrine transporters (hNET) was carried out. None of the synthesized compounds were found to be stronger than benztropine, and none were selective for inhibition of binding over monoamine uptake.


Asunto(s)
Benzotropina/síntesis química , Técnicas Químicas Combinatorias , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática/efectos de los fármacos , Inhibidores de Captación de Dopamina/síntesis química , Proteínas de Transporte de Noradrenalina a través de la Membrana Plasmática/efectos de los fármacos , Proteínas de Transporte de Serotonina en la Membrana Plasmática/efectos de los fármacos , Benzotropina/análogos & derivados , Benzotropina/química , Línea Celular , Células Cultivadas , Dopamina/farmacocinética , Inhibidores de Captación de Dopamina/química , Inhibidores de Captación de Dopamina/farmacología , Diseño de Fármacos , Evaluación Preclínica de Medicamentos , Humanos , Estructura Molecular , Norepinefrina/farmacocinética , Serotonina/farmacocinética
16.
Bioorg Med Chem Lett ; 14(12): 3295-8, 2004 Jun 21.
Artículo en Inglés | MEDLINE | ID: mdl-15149693

RESUMEN

A series of racemic 6-hydroxy and carboalkoxy substituted-4('),4"-difluorobenztropines was synthesized and evaluated for binding at the dopamine (DAT), the serotonin (SERT), the norepinephrine (NET) transporters, and the muscarinic M1 receptor. Each of the analogues displaced [(3)H]WIN 35,428 (DAT) with a range of affinities from 5.81 to 175 nM and [(3)H]pirenzepine (M1), with a range of affinities ( K(i)= -8430 nM). Binding affinities at the SERT and the NET were generally low.


Asunto(s)
Benzotropina/química , Glicoproteínas de Membrana/metabolismo , Proteínas de Transporte de Membrana/metabolismo , Proteínas del Tejido Nervioso/metabolismo , Receptor Muscarínico M1/metabolismo , Simportadores/metabolismo , Benzotropina/metabolismo , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática , Proteínas de Transporte de Noradrenalina a través de la Membrana Plasmática , Unión Proteica/fisiología , Proteínas de Transporte de Serotonina en la Membrana Plasmática
17.
J Pharmacol Exp Ther ; 307(2): 801-8, 2003 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-12966155

RESUMEN

The N-substituted 3alpha-[bis(4'-fluorophenyl)methoxy]tropanes (AHN 2-003, AHN 1-055, AHN 2-005, and JHW 007) bind with high affinity to the dopamine transporter and inhibit dopamine uptake more potently than cocaine, but they demonstrate behavioral profiles in animal models of psychostimulant abuse that are unlike that of cocaine. The objective of this study was to characterize the in vitro permeability, brain distribution, and pharmacokinetics of the benztropine (BZT) analogs. Transport studies of cocaine and the BZT analogs (10-4 M) were conducted across bovine brain microvessel endothelial cells. Male Sprague-Dawley rats (approximately 300 g) were administered BZT analogs (10 mg/kg) or cocaine (5 mg/kg) via the tail vein. Blood and brain samples were collected over 36 h and assayed using UV-high-performance liquid chromatography. Transport of both AHN 1-055 (2.15 x 10-4 cm/s) and JHW 007 (2.83 x 10-4 cm/s) was higher (p < 0.05) than that of cocaine (1.63 x 10-4 cm/s). The volume of distribution (12.3-30.5 l/kg) of the analogs was significantly higher than cocaine (0.9 l/kg). The BZT analogs displayed a > or =8-fold higher elimination half-life (4.12-16.49 h) compared with cocaine (0.49 h). The brain-to-plasma partition coefficients were at least two-fold higher for the BZTs versus cocaine, except for AHN 2-003. The BZT analogs are highly permeable across the blood-brain barrier and possess a pharmacokinetic profile different from that of cocaine. These characteristics, in addition to their distinctive behavioral profiles, suggest that the BZT analogs may be promising candidates for the treatment of cocaine abuse.


Asunto(s)
Benzotropina/farmacocinética , Barrera Hematoencefálica/metabolismo , Encéfalo/metabolismo , Cocaína/farmacocinética , Animales , Benzotropina/química , Transporte Biológico , Bovinos , Masculino , Ratas , Ratas Sprague-Dawley , Distribución Tisular , Vasoconstrictores/farmacocinética
18.
J Med Chem ; 44(25): 4453-61, 2001 Dec 06.
Artículo en Inglés | MEDLINE | ID: mdl-11728190

RESUMEN

3alpha-(diphenylmethoxy)tropane (benztropine) and its analogues are tropane ring-containing dopamine uptake inhibitors that display binding and behavioral profiles that are distinct from cocaine. We previously prepared a benztropine-based photoaffinity label [125I]-(N-[4-(4'-azido-3'-iodophenyl)butyl]-3alpha-[bis(4'-fluorophenyl)methoxy]tropane, [125I]1, that covalently attached to the 1-2 transmembrane spanning region of the dopamine transporter (DAT). This was in contrast to the 4-7 transmembrane spanning region labeled by a cocaine-based photoaffinity label, [125I] 2 (RTI 82). To characterize further these different binding domains, photoaffinity ligands that had the 4'-azido-3'-iodophenyl substituent extended from the same position on the tropane ring were desirable. Thus, identification of the optimal alkyl linker between this substituent and the tropane nitrogen in the benztropine series was investigated to ultimately prepare the identical N-substituted analogue of 2. In this pursuit, the N-[4-(4'-azido-3'-iodophenyl)propyl] analogue of 3alpha-[bis(4'-fluorophenyl)methoxy]tropane (9a) was synthesized as well as two isothiocyanate analogues that do not require photoactivation (10a,b) for irreversible binding. The synthesis of these target compounds was achieved using a modification of the strategy developed for 1. Evaluation of these compounds for displacing [3H]WIN 35 428 binding at DAT in rat caudate putamen revealed that the 4'-azido-3'-iodophenylbutyl substituent, found in 1, provided optimal binding affinity and was chosen to replace the N-CH3 group on 2. Both the 4'-azido-3'-iodophenyl- and the 4'-isothiocyanatophenylbutyl analogues of 2 (25 and 26, respectively) were synthesized. Both products bound to DAT with comparable potency (IC(50) = 30 nM) to RTI 82 (2). In addition, compound 26 demonstrated wash-resistant displacement of [3H]WIN 35 428 in HEK 293 cells stably transfected with hDAT. These ligands will provide important tools for further characterizing the binding domains for tropane-based dopamine uptake inhibitors at the DAT.


Asunto(s)
Benzotropina/análogos & derivados , Benzotropina/síntesis química , Cocaína/análogos & derivados , Inhibidores de Captación de Dopamina/síntesis química , Dopamina/metabolismo , Isotiocianatos/síntesis química , Glicoproteínas de Membrana , Proteínas de Transporte de Membrana/metabolismo , Proteínas del Tejido Nervioso , Tropanos/síntesis química , Animales , Azidas/metabolismo , Benzotropina/química , Benzotropina/metabolismo , Unión Competitiva , Línea Celular , Cocaína/metabolismo , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática , Inhibidores de Captación de Dopamina/química , Inhibidores de Captación de Dopamina/metabolismo , Humanos , Técnicas In Vitro , Isotiocianatos/química , Isotiocianatos/metabolismo , Ligandos , Masculino , Putamen/metabolismo , Ensayo de Unión Radioligante , Ratas , Ratas Sprague-Dawley , Relación Estructura-Actividad , Tropanos/química , Tropanos/metabolismo
19.
Psychopharmacology (Berl) ; 154(4): 362-74, 2001 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-11349389

RESUMEN

RATIONALE: Previous SAR studies demonstrated that small halogen substitutions on the diphenylether system of benztropine (BZT), such as a para-Cl group, retained high affinity at the cocaine binding site on the dopamine transporter. Despite this high affinity, the compounds generally had behavioral effects different from those of cocaine. However, compounds with meta-Cl substitutions had effects more similar to those of cocaine. OBJECTIVES: A series of phenyl-ring analogs of benztropine (BZT) substituted with 3'-, 4'-, 3',4"- and 4',4"-position Cl-groups were synthesized and their pharmacology was evaluated in order to assess more fully the contributions to pharmacological activity of substituents in these positions. METHODS: Compounds were synthesized and their pharmacological activity was assessed by examining radioligand binding and behavioral techniques. RESULTS: All of the compounds displaced [3H]WIN 35,428 binding with affinities ranging from 20 to 32.5 nM. Affinities at norepinephrine ([3H]nisoxetine) and serotonin ([3H]citalopram) transporters, respectively, ranged from 259 to 5120 and 451 to 2980 nM. Each of the compounds also inhibited [3H]pirenzepine binding to muscarinic M1 receptors, with affinities ranging from 0.98 to 47.9 nM. Cocaine and the BZT analogs produced dose-related increases in locomotor activity in mice. However, maximal effects of the BZT analogs were uniformly less than those produced by cocaine, and were obtained 2-3 h after injection compared to the relatively rapid onset (within 30 min) of cocaine effects. In rats trained to discriminate i.p. saline from 29 mumol/kg cocaine (10 mg/kg), cocaine produced a dose-related increase in responding on the cocaine lever, reaching 100% at the training dose; however, none of the BZT analogs fully substituted for cocaine, with maximum cocaine responding from 20 to 69%. Despite their reduced efficacy compared to cocaine in cocaine discrimination, none of the analogs antagonized the effects of cocaine. As has been reported previously for 4'-Cl-BZT, the cocaine discriminative-stimulus effects were shifted left-ward by co-administration of the present BZT analogs. CONCLUSIONS: The present results indicate that although the BZT analogs bind with relatively high affinity and selectivity at the dopamine transporter, their behavioral profile is distinct from that of cocaine. The present results suggest that analogs of BZT may be useful as treatments for cocaine abuse in situations in which an agonist treatment is indicated. These compounds possess features such as reduced efficacy compared to cocaine and a long duration of action that may render them particularly useful leads for the development of therapeutics for cocaine abusers.


Asunto(s)
Antiparkinsonianos/metabolismo , Benzotropina/análogos & derivados , Benzotropina/metabolismo , Proteínas Portadoras/metabolismo , Cocaína/análogos & derivados , Cocaína/metabolismo , Inhibidores de Captación de Dopamina/metabolismo , Proteínas de Transporte de Membrana , Proteínas del Tejido Nervioso , Simportadores , Animales , Antiparkinsonianos/química , Antiparkinsonianos/farmacología , Benzotropina/química , Benzotropina/farmacología , Cocaína/química , Cocaína/farmacología , Discriminación en Psicología/efectos de los fármacos , Discriminación en Psicología/fisiología , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática , Inhibidores de Captación de Dopamina/química , Inhibidores de Captación de Dopamina/farmacología , Relación Dosis-Respuesta a Droga , Masculino , Glicoproteínas de Membrana/metabolismo , Ratones , Actividad Motora/efectos de los fármacos , Actividad Motora/fisiología , Proteínas de Transporte de Noradrenalina a través de la Membrana Plasmática , Ratas , Ratas Sprague-Dawley , Tiempo de Reacción/efectos de los fármacos , Tiempo de Reacción/fisiología , Receptor Muscarínico M1 , Receptores Muscarínicos/metabolismo , Proteínas de Transporte de Serotonina en la Membrana Plasmática
20.
Bioorg Med Chem Lett ; 11(6): 823-7, 2001 Mar 26.
Artículo en Inglés | MEDLINE | ID: mdl-11277529

RESUMEN

6-Methoxylated and 8-oxygenated benztropines were prepared and evaluated for their DAT and SERT activity (binding and uptake inhibition). Methoxylation at the two-carbon bridge of benztropine produced a novel class of potent and selective DAT ligands. An interesting enantioselectivity was also observed for this new class of chiral benztropines. The inactivity of the 8-oxygenated analogues seems to point out that, unlike cocaine and its analogues, interactions of benztropine ligands with DAT may be strongly governed by the nitrogen atom.


Asunto(s)
Benzotropina/farmacología , Proteínas Portadoras/metabolismo , Glicoproteínas de Membrana , Proteínas de Transporte de Membrana , Antagonistas Muscarínicos/farmacología , Proteínas del Tejido Nervioso , Benzotropina/química , Proteínas Portadoras/efectos de los fármacos , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática , Ligandos , Conformación Molecular , Antagonistas Muscarínicos/química , Relación Estructura-Actividad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA